Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Size: px
Start display at page:

Download "Pharmacy Coverage Guidelines are subject to change as new information becomes available."

Transcription

1 capsule, VASCEPA (icosapent ethyl) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exce ptions to these guidelines. The section identified as Description defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage. The section identified as Criteria defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational. State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity. Pharmacy Coverage Guidelines are subject to change as new information becomes available. For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable. BLUE CROSS, BLUE SHIELD and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ. Description: Epanova, Lovaza (brand & generic), Omtryg, and Vasepa are omega-3 fatty acids indicated as an adjunct to diet and exercise to reduce triglyceride levels in adults with severe (500 mg/dl or more) hypertriglyceridemia. The Endocrine Society guidelines for the treatment of hypertriglyceridemia recommends that omega-3 fatty acids may be considered for triglyceride levels greater than 1,000 mg/dl and may be used alone or in combination with HMG-CoA reductase inhibitors (or statin). Secondary causes of hyperlipidemia should be ruled out prior to therapy. The effect, if any, of omega-3 fatty acids on the risk of pancreatitis or cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia is not known. In general, omega-3 fatty acids are a mixture of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Lovaza (brand & generic) omega-3 acid ethyl esters capsules contain at least 900 mg of ethyl esters of omega-3 fatty acids sourced from fish oil, which are predominantly EPA (approximately 465 mg) and DHA (approximately Page 1 of 7

2 375 mg). Epanova is a carboxylic acid free fatty acid composed of a combination of polyunsaturated fatty acids. It includes 50-60% EPA, 15-25% DHA, and other omega-3 fatty acids. Omtryg is an omega-3 fatty acid ethyl esters A containing > 75% EPA and DHA. Icosapent ethyl is an ethyl ester of EPA obtained from fish oil; however, it contains at least 96% EPA and does not contain DHA. Several clinical studies have demonstrated that icosapent ethyl and prescription omega-3 acid ethyl esters can effectively lower triglycerides, as well as positively impact other lipid parameters when used as monotherapy or in combination with fenofibrate or a statin. Recommendations in clinical guidelines regarding the use of omega-3 fatty acids are varied. Older guidelines suggest omega-3 fatty acids may reduce the risk of cardiovascular disease and may be reasonable for cardiovascular disease risk reduction, while newer guidelines do not address the use or recommend against the use of omega-3 fatty acids for reducing the risk of cardiovascular disease due to limited data. In general, therapeutic lifestyle changes, including diet, exercise, and smoking cessation, remain an essential modality in the management of patients with hypercholesterolemia. When LDL lowering is required, initial treatment with a statin is recommended and considered first line therapy for patients with established coronary heart disease (CHD) or CHD equivalents. The exact mechanism by which these agents reduce triglyceride levels is not completely understood. Possible mechanisms include: inhibition of acyl CoA: 1,2 diacylglycerol acyltransferase (DGAT), increased hepatic mitochondrial and hepatic peroxisomal beta-oxidation, reduction in the hepatic synthesis of triglycerides, or an increase in plasma lipoprotein lipase activity. They may also reduce the hepatic synthesis of triglycerides because EPA and DHA are poor substrates for the enzymes responsible for triglyceride synthesis, and EPA and DHA inhibit esterification of other fatty acids. The majority of EPA circulating in plasma is incorporated in phospholipids, triglycerides and cholesteryl esters, and <1% is present as the unesterified fatty acid. Greater than 99% of unesterified EPA is bound to plasma proteins. Icosapent ethyl is de-esterified during absorption to its active metabolite EPA. EPA is mainly metabolized by the liver via beta-oxidation similar to dietary fatty acids. Beta oxidation splits the long carbon chain of EPA into acetyl Coenzyme A, which is converted into energy via the Krebs cycle. Cytochrome P450-mediated metabolism is a minor pathway of elimination of EPA. Definitions: Drug related events: Ineffective / failure Use of a drug employing optimal doses (FDA-recommended doses) for optimal duration; where the condition being treated has not improved or worsened A request for branded agent due to generic drug failure or ineffectiveness will be assessed for potential approval with documentation of use of optimal dose / duration of the generic product and meeting other criteria within the coverage guideline. When the drug in question is a combination product, there must be documentation of failure / ineffectiveness of concurrent use (each ingredient used at the same time) of Page 2 of 7

3 individual generic components. When the drug in question is a low dose formulation, there must be documentation of failure / ineffectiveness of low dose generic formulation. Adverse Drug Event: Allergic reaction / Hypersensitivity / Intolerance Use of a drug produced a significant reaction where continued use of the drug places the individual at risk for either lack of improvement or worsening of the condition being treated or at risk for harm and the concern is documented in medical record. A significant adverse drug event is when an individual s outcome is death, life-threatening, hospitalization (initial or prolonged), disability resulting in a significant, persistent, or permanent change, impairment, damage or disruption in the individuals body function/structure, physical activities or quality of life, or requires intervention to prevent permanent impairment or damage. Allergic reaction / hypersensitivity may or may not involve the active ingredient. When the active ingredient is involved, use of same or a chemically similar agent places the individual at risk for harm when the same or chemically similar agent is used. The subsequent reaction may be the same as the original reaction or a more exaggerated response may be seen, potentially placing the individual at even greater risk for harm. If the reaction occurred from the active/main generic ingredient; request for branded agent with same active ingredient will not be considered unless it is proven (documented) that active ingredient did not cause reaction and the request meets other criteria within the coverage guideline Intolerance these events represent circumstance(s) where use of a drug produced a significant reaction and continued use may result in non-adherence to proposed therapy and this concern is documented in medical record Contraindication Use of a drug that is not recommended by the manufacturer or FDA labelling Use of any drug in the face of a contraindication is outside of the FDA and manufacturer s labelled recommendation and is considered investigational or experimental Non-adherence Individual does not follow prescribe regimen that places the individual at risk for lack of improvement or worsening of the condition being treated and this concern is documented in medical record Precertification: Precertification (Prior Authorization) is required for members with a Blue Cross Blue Shield of Arizona (BCBSAZ) pharmacy benefit for medication(s) or product(s) indicated in this guideline. This Pharmacy Coverage Guideline does not apply to FEP or other states Blues Plans. Information about medications that require precertification is available at Page 3 of 7

4 Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements. All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums. Criteria: See Resources section for FDA-approved dosage. Precertification for Epanova, Lovaza, Omtryg, and Vascepa requires completion of the specific request form in its entirety. All requested data must be provided. Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) or to Incomplete forms will be returned. FDA-approved product labeling (indication, age, dosage, testing, contraindications, exclusions, etc.) of Epanova, Lovaza, Omtryg, and Vascepa is considered medically necessary when ALL of the following criteria are met: 1. Individual is 18 years of age and older 2. Medical record documentation of a confirmed diagnosis of severe ( 500 mg/dl) hypertriglyceridemia 3. Individual is compliant with a lipid-lowering diet and exercise program 4. Absence of ALL of the following contraindications: Known hypersensitivity (e.g., anaphylactic reaction) to Epanova, Lovaza, Omtryg, and Vascepa or any of its components 5. Individual is unable to use generic prescription products (i.e., generic Lovaza) due to either ineffective, contraindicated, or not tolerated Epanova, Lovaza, Omtryg, and Vascepa for all other indications not previously listed is considered experimental or investigational based upon: 1. Lack of final approval from the Food and Drug Administration, and 2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes, and 3. Insufficient evidence to support improvement of the net health outcome, and 4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives, and 5. Insufficient evidence to support improvement outside the investigational setting. This includes but is not limited to the following: Page 4 of 7

5 Prevention of coronary heart disease IgA Nephropathy Inflammatory bowel disease Rheumatoid arthritis Psoriasis Pancreatitis Macular degeneration Dry eye syndrome Mood disorders Renal disease (glomerular kidney disease) Systemic lupus erythematosus Osteoporosis History: Date: Activity: Pharmacy and Therapeutics review Adopted guideline Director Pharmacy Mgmt. review Development Criteria Revisions: Date: Criteria: Revisions: Resources: Epanova. Package Insert. Reference ID Revised by manufacturer 5/2014. Accessed Lovaza. Package Insert. Reference ID LVZ:12PI. Revised by manufacturer 5/2014. Accessed Omtryg. Package Insert. Reference ID Revised by manufacturer 4/2014. Accessed Vascepa. Package Insert. Reference ID PP00120G. Revised by manufacturer 1/2015. Accessed FDA-approved indication and dosage: Page 5 of 7

6 Indication EPANOVA, a fish oil-derived mixture of free fatty acids primarily composed of EPA and DHA, is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe ( 500 mg/dl) hypertriglyceridemia. The effect of EPANOVA on the risk for pancreatitis has not been determined. The effect of EPANOVA on cardiovascular mortality and morbidity has not been determined. LOVAZA is a combination of ethyl esters of omega-3 fatty acids, principally EPA and DHA, indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe ( 500 mg/dl) hypertriglyceridemia (HTG). The effect of LOVAZA on the risk for pancreatitis has not been determined. The effect of LOVAZA on cardiovascular mortality and morbidity has not been determined. OMTRYG is a combination of ethyl esters of omega-3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe ( 500 mg/dl) hypertriglyceridemia. The effect of OMTRYG on the risk for pancreatitis has not been determined. The effect of OMTRYG on cardiovascular mortality and morbidity has not been determined. Recommended Dose The dosage of EPANOVA is 2 grams (2 capsules) or 4 grams (4 capsules) once daily. Individualize therapy according to patient response and tolerability. In clinical trials, EPANOVA was administered without regard to meals. Patients should be advised to swallow EPANOVA capsules whole. Do not break open, crush, dissolve or chew EPANOVA. The daily dose of LOVAZA is 4 grams per day taken as a single 4-gram dose (4 capsules) or as two 2-gram doses (2 capsules given twice daily). Patients should be advised to swallow LOVAZA capsules whole. Do not break open, crush, dissolve or chew LOVAZA. The daily dose of OMTRYG is 4 capsules per day taken as a single dose or as 2 capsules given twice daily. OMTRYG should be taken with meals. Patients should be advised to swallow OMTRYG capsules whole. Do not break open, crush, dissolve or chew OMTRYG. Page 6 of 7

7 VASCEPA is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe ( 500 mg/dl) hypertriglyceridemia. The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. The effect of VASCEPA on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. The daily dose of VASCEPA is 4 grams per day taken as 2 capsules twice daily with food. Patients should be advised to swallow VASCEPA capsules whole. Do not break open, crush, dissolve or chew VASCEPA. Page 7 of 7

TRAMADOL HYDROCHORIDE ER oral biphasic capsule

TRAMADOL HYDROCHORIDE ER oral biphasic capsule TRAMADOL HYDROCHORIDE ER oral biphasic capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This

More information

NUVIGIL (armodafinil) oral tablet

NUVIGIL (armodafinil) oral tablet NUVIGIL (armodafinil) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

ZYTIGA (abiraterone acetate) oral tablet

ZYTIGA (abiraterone acetate) oral tablet ZYTIGA (abiraterone acetate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL FORMULATIONS: ABSTRAL (fentanyl citrate) sublingual tablet ACTIQ (fentanyl citrate) transmucosal lozenge FENTORA (fentanyl citrate) buccal tablet LAZANDA (fentanyl

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. TOPICAL CLINDAMYCIN PRODUCTS: ACANYA (clindamycin phosphate-benzoyl peroxide) gel BENZACLIN (clindamycin phosphate-benzoyl peroxide) gel CLEOCIN-T (clindamycin phosphate) gel, lotion, solution, swab CLINDAGEL

More information

Onychomycosis Therapy: JUBLIA (efinaconazole) topical solution, 10% and KERYDIN (tavaborole) topical solution, 5%

Onychomycosis Therapy: JUBLIA (efinaconazole) topical solution, 10% and KERYDIN (tavaborole) topical solution, 5% KERYDIN (tavaborole) topical solution, 5% Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

JUXTAPID (lomitapide) oral capsule

JUXTAPID (lomitapide) oral capsule JUXTAPID (lomitapide) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

HORIZANT (gabapentin enacarbil) extended-release tablet

HORIZANT (gabapentin enacarbil) extended-release tablet HORIZANT (gabapentin enacarbil) extended-release tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit

More information

BELBUCA (buprenorphine) buccal film

BELBUCA (buprenorphine) buccal film BELBUCA (buprenorphine) buccal film Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Omega-3 Fatty Acid Products

Omega-3 Fatty Acid Products Omega-3 Fatty Acid Products Policy Number: 5.01.563 Last Review: 7/2016 Origination: 6/2014 Next Review: 7/2017 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for the

More information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/15/16 SECTION: DRUGS LAST REVIEW DATE: 01/17/17 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/15/16 SECTION: DRUGS LAST REVIEW DATE: 01/17/17 LAST CRITERIA REVISION DATE: ARCHIVE DATE: ENBREL (etanercept) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Therapeutic Options for Triglyceride Lowering

Therapeutic Options for Triglyceride Lowering Therapeutic Options for Triglyceride Lowering Dave L. Dixon, PharmD, BCPS, CDE, CLS, AACC, FNLA Associate Professor and Vice-Chair of Clinical Services Department of Pharmacotherapy & Outcomes Science

More information

Page 1 of 11 HIGHLIGHTS OF PRESCRIBING INFORMATION

Page 1 of 11 HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION VASCEPA (icosapent ethyl) Capsules, for oral use Initial U.S. Approval: 2012 ------------------------WARNINGS and PRECAUTIONS------------------------- In patients

More information

SAMSCA (tolvaptan) oral tablet

SAMSCA (tolvaptan) oral tablet SAMSCA (tolvaptan) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at or FDA at FDA-1088 or

To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at or FDA at FDA-1088 or HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LOVAZA safely and effectively. See full prescribing information for LOVAZA. LOVAZA (omega-3-acid

More information

High ( 50%) Restrictions

High ( 50%) Restrictions MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/17/2016 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/15, 5/14, 9/11, 5/11, LOB AFFECTED: Medi-Cal,

More information

HEREDITARY ANGIOEDEMA MEDICATION THERAPY

HEREDITARY ANGIOEDEMA MEDICATION THERAPY HEREDITARY ANGIOEDEMA MEDICATION THERAPY Coverage for services, procedures, medical devices drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical

More information

Medical Coverage Guidelines are subject to change as new information becomes available.

Medical Coverage Guidelines are subject to change as new information becomes available. ENBREL (etanercept) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline

More information

Prescription and Next-Generation Omega-3 Fatty Acids

Prescription and Next-Generation Omega-3 Fatty Acids Prescription and Next-Generation Omega-3 Fatty Acids Event Type Live Online Expiration Date 2/10/2017 Credits 1 Contact Hour Target Audience Nurses, Pharmacists, Pharmacy Technicians Program Overview Recommendations

More information

AUBAGIO (teriflunomide) oral tablet

AUBAGIO (teriflunomide) oral tablet AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Very High Triglycerides

Very High Triglycerides Understanding Very High Triglycerides For more information, visit CardioSmart.org/VHTG Understanding Very High Triglycerides Keeping track of your cholesterol is a very good idea. That s also true for

More information

MULTIPLE SCLEROSIS INJECTABLE THERAPY

MULTIPLE SCLEROSIS INJECTABLE THERAPY MULTIPLE SCLEROSIS INJECTABLE THERAPY Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical

More information

Prescribing Information

Prescribing Information The format of this leaflet was determined by the Ministry of Health and its content was checked and approved by it. Omacor Prescribing Information 1 NAME OF THE MEDICINAL PRODUCT OMACOR, 1000 mg, soft

More information

OMEGA-3-ACID ETHYL ESTERS Capsules, USP for oral use Initial U.S. Approval: 2004

OMEGA-3-ACID ETHYL ESTERS Capsules, USP for oral use Initial U.S. Approval: 2004 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use omega-3-acid ethyl esters capsules, USP safely and effectively. See full prescribing information

More information

NCEP Drug Treatment. Major Classes of Drugs Available Affecting Lipoprotein Metabolism

NCEP Drug Treatment. Major Classes of Drugs Available Affecting Lipoprotein Metabolism Major Classes of Drugs Available Affecting Lipoprotein Metabolism HMG CoA reductase inhibitors lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin cholestyramine, colestipol, colesevelam crystalline,

More information

Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs. August 2005;65(8):1051-9

Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs. August 2005;65(8):1051-9 Omega-3 fatty acids in the treatment of psychiatric disorders. 1 Peet M, Stokes C. Drugs. August 2005;65(8):1051-9 FROM ABSTRACT: The importance of omega-3 fatty acids for physical health is now well recognised

More information

Primary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing

Primary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Primary Care Management of Women with Hyperlipidemia Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Objectives: Define dyslipidemia in women Discuss the investigation process leading

More information

Triglycerides are an important measure of heart health. Here's why triglycerides matter and what to do if your triglycerides are too high.

Triglycerides are an important measure of heart health. Here's why triglycerides matter and what to do if your triglycerides are too high. Diseases and Conditions High cholesterol Triglycerides are an important measure of heart health. Here's why triglycerides matter and what to do if your triglycerides are too high. By Mayo Clinic Staff

More information

Summary of Product Characteristics

Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Trimega 1000 mg Capsules Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 1000 mg Omega-3-acid ethyl esters 90, comprising

More information

September 2014. Strategy or Medications Added or Modified Remove belladonna alkaloidsphenobarbital. Therapeutic Class/Drug Name.

September 2014. Strategy or Medications Added or Modified Remove belladonna alkaloidsphenobarbital. Therapeutic Class/Drug Name. The following changes to the Neighborhood formulary were recently approved by the Pharmacy and s (P&T) Committee. These changes are effective immediately unless otherwise indicated. Belladonna alkaloidsphenobarbital

More information

TESTOSTERONE REPLACEMENT THERAPY

TESTOSTERONE REPLACEMENT THERAPY TESTOSTERONE REPLACEMENT THERAPY Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

SEDICO Newsletter Volume 7 Omega-3 Fatty Acids & Statins

SEDICO Newsletter Volume 7 Omega-3 Fatty Acids & Statins Omega-3 fatty acids on heart function (including anti-arrhythmic effects), hemo-dynamics (cardiac mechanics) and arterial endothelial function. The link between omega-3 fatty acids and CVD risk reduction

More information

Medication Use in the Elderly. Rebecca Beyth, MD, MSc Associate Professor, NF/SGVHS, and Dept of Aging and Geriatric UF College of Medicine 10/6/06

Medication Use in the Elderly. Rebecca Beyth, MD, MSc Associate Professor, NF/SGVHS, and Dept of Aging and Geriatric UF College of Medicine 10/6/06 Medication Use in the Elderly Rebecca Beyth, MD, MSc Associate Professor, NF/SGVHS, and Dept of Aging and Geriatric UF College of Medicine 10/6/06 Significance Persons > 65 years of age compose only about

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Omega 3-acid-ethyl esters 1000mg soft capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One capsule contains 1000 mg Omega-3-Acid Ethyl

More information

Fish, fish oils, n-3 polyunsaturated fatty acids and cardiovascular health

Fish, fish oils, n-3 polyunsaturated fatty acids and cardiovascular health Position statement Fish, fish oils, n-3 polyunsaturated fatty acids and cardiovascular health Updated November 2008 This position statement was developed to provide recommendations to the general population

More information

Prior Authorization Protocol ALTOPREV (lovastatin extended release), CRESTOR (rosuvastatin), LIVALO (pitavastatin), VYTORIN (ezetimibe/simvastatin)

Prior Authorization Protocol ALTOPREV (lovastatin extended release), CRESTOR (rosuvastatin), LIVALO (pitavastatin), VYTORIN (ezetimibe/simvastatin) ALTOPREV (lovastatin extended release), CRESTOR (rosuvastatin), LIVALO (pitavastatin), VYTORIN (ezetimibe/simvastatin) Coverage of drugs is first determined by the member`s pharmacy or medical benefit.

More information

Anti-Atheroscrerotic Drugs

Anti-Atheroscrerotic Drugs Anti-Atheroscrerotic Drugs Masuko Ushio-Fukai, PhD, FAHA Dept. of Pharmacology University of Illinois at Chicago Anti-Atherogenic Drugs: Treatment of Hyperlipidemias Knowledge Objectives: 1) Know the mechanism

More information

Viberzi. Viberzi (eluxadoline) Description

Viberzi. Viberzi (eluxadoline) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.07 Subsection: Gastrointestinal Agents Original Policy Date: July 24, 2015 Subject: Viberzi Page:

More information

11/27/2012. Evaluation and Treatment of Hypertriglyceridemia. Lars Berglund, M.D., Ph.D. John Brunzell, M.D.

11/27/2012. Evaluation and Treatment of Hypertriglyceridemia. Lars Berglund, M.D., Ph.D. John Brunzell, M.D. Evaluation and Treatment of Hypertriglyceridemia Lars Berglund, M.D., Ph.D. John Brunzell, M.D. 1 Disclosures Lars Berglund, MD, PhD: Consultant, Danone; Stockholder, Novo Nordisk, Pfizer John Brunzell,

More information

RECLAST (zoledronic acid) INJECTION

RECLAST (zoledronic acid) INJECTION RECLAST (zoledronic acid) INJECTION Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage

More information

VYTORIN : ATTACKING CHOLESTEROL WITH A DUAL MECHANISM

VYTORIN : ATTACKING CHOLESTEROL WITH A DUAL MECHANISM Volume 20, Issue 6 March 2005 VYTORIN : ATTACKING CHOLESTEROL WITH A DUAL MECHANISM Benjamin Spitz, Pharm.D. Candidate In July 2004, the National Cholesterol Education Panel (NCEP) published an update

More information

GENETIC TESTING FOR WHOLE EXOME AND WHOLE GENOME SEQUENCING FOR DIAGNOSIS OF GENETIC DISORDERS

GENETIC TESTING FOR WHOLE EXOME AND WHOLE GENOME SEQUENCING FOR DIAGNOSIS OF GENETIC DISORDERS FOR DIAGNOSIS OF GENETIC DISORDERS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices

More information

Medication Information for Parents and Teachers

Medication Information for Parents and Teachers Medication Information for Parents and Teachers Omega-3 Fatty Acids Epanova, Lovaza General Information About Medication Each child and adolescent is different. No one has exactly the same combination

More information

Recommendations for the Diagnosis and Treatment of. For complete guideline: Can J Cardiol Vol 22 No 11 September 2006

Recommendations for the Diagnosis and Treatment of. For complete guideline: Can J Cardiol Vol 22 No 11 September 2006 Recommendations for the Diagnosis and Treatment of Dyslipidemia Introduction For complete guideline: Can J Cardiol Vol 22 No 11 September 2006 Screening Recommendations - full fasting lipid profile Children

More information

Dyslipidemia. Hisham Aljadhey, PharmD, PhD

Dyslipidemia. Hisham Aljadhey, PharmD, PhD Dyslipidemia Hisham Aljadhey, PharmD, PhD Etiology Primary hyperlipidemia Familial hypercholesterolemia Secondary hyperlipidemia Disease states: hypothyroidism, nephrotic syndrome, obesity, DM, alcoholism

More information

REACH Risk Evaluation to Achieve Cardiovascular Health

REACH Risk Evaluation to Achieve Cardiovascular Health Dyslipidemia and type 1 diabetes mellitus History: A 15-year-old girl is seen in the endocrinology clinic for a routine follow-up visit for type 1 diabetes. She was diagnosed with diabetes at 12 years

More information

Omega-3-acid ethyl esters (K85EE)

Omega-3-acid ethyl esters (K85EE) Technical Information May 2015 Supersedes issue dated September 2014 mega-3-s (K85EE) 03_081400e-01/Page 1 of 6 Last change WM-No. 129069 = Registered trademark of BASF Ph. Eur., USP 03_081400e-01 May

More information

Nursing 113. Pharmacology Principles

Nursing 113. Pharmacology Principles Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics

More information

Welchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes

Welchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

More information

Medical Coverage Guidelines are subject to change as new information becomes available.

Medical Coverage Guidelines are subject to change as new information becomes available. LIVER TRANSPLANT Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must

More information

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181

More information

Benlysta. Benlysta (belimumab) Description

Benlysta. Benlysta (belimumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.11.01 Subject: Benlysta Page: 1 of 5 Last Review Date: September 18, 2015 Benlysta Description Benlysta

More information

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181

More information

Learn More About Product Labeling

Learn More About Product Labeling Learn More About Product Labeling Product label The product label is developed during the formal process of review and approval by regulatory agencies of any medicine or medical product. There are specific

More information

Guidelines for the management of dyslipidaemia in patients with diabetes mellitus

Guidelines for the management of dyslipidaemia in patients with diabetes mellitus Guidelines for the management of dyslipidaemia in patients with diabetes mellitus Quick reference guide More than 60% of type 2 diabetic subjects in the Eastern Mediterranean Region have some degree of

More information

GENETIC TESTING FOR CADASIL SYNDROME

GENETIC TESTING FOR CADASIL SYNDROME GENETIC TESTING FOR CADASIL SYNDROME Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical

More information

High Blood Cholesterol

High Blood Cholesterol National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour

More information

Optimal Health for Everyone Foundations of Optimal Health Regimen

Optimal Health for Everyone Foundations of Optimal Health Regimen Optimal Health for Everyone Foundations of Optimal Health Regimen The 21 st century is stressful and fast-paced, with less healthy air, water and foods. The Foundations of Optimal Health Regimen is designed

More information

Public Assessment Report. Scientific discussion

Public Assessment Report. Scientific discussion Public Assessment Report Scientific discussion Ésteres etílicos 90 dos ácidos ómega-3 Glenmark 1000 mg, Soft Gel Capsules (Omega-3-Acid Ethyl Esters 90) PT/H/0779/001/DC This module reflects the scientific

More information

FORTH VALLEY. LIPID LOWERING GUIDELINES v4 May 2010

FORTH VALLEY. LIPID LOWERING GUIDELINES v4 May 2010 FORTH VALLEY LIPID LOWERING GUIDELINES v4 May 2010 This guideline applies to people over 16 years of age. This guideline is not intended to serve as a standard of medical care or be applicable in every

More information

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized

More information

STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA

STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan.

More information

Cholesterol Guidelines: Review of Adult Treatment Panel (ATP) III Guidelines and Beyond

Cholesterol Guidelines: Review of Adult Treatment Panel (ATP) III Guidelines and Beyond Cholesterol Guidelines: Review of Adult Treatment Panel (ATP) III Guidelines and Beyond Heather Dacus, DO, MPH Medical Director Bureau of Chronic Disease Services New York State Department of Health Learning

More information

MAGNETIC RESONANCE IMAGING (MRI) TARGETED BIOPSY OF THE PROSTATE

MAGNETIC RESONANCE IMAGING (MRI) TARGETED BIOPSY OF THE PROSTATE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon

More information

AUTONOMIC NERVOUS SYSTEM TESTING

AUTONOMIC NERVOUS SYSTEM TESTING AUTONOMIC NERVOUS SYSTEM TESTING Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices

More information

Measure #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care

Measure #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care Measure #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Understanding and Managing Your. Triglycerides

Understanding and Managing Your. Triglycerides Understanding and Managing Your Triglycerides What are Triglycerides? There are several types are one of several types of fat in your body, and triglycerides are the most common. Along with LDL ( bad )

More information

5.07.09. Aubagio. Aubagio (teriflunomide) Description

5.07.09. Aubagio. Aubagio (teriflunomide) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)

More information

Improving HDL Cholesterol: How, Why and NOW! Len Kravitz, Ph.D.

Improving HDL Cholesterol: How, Why and NOW! Len Kravitz, Ph.D. Improving HDL Cholesterol: How, Why and NOW! Len Kravitz, Ph.D. Cardiovascular disease, the number one cause of mortality with men and women in the U.S., is a cluster of problems of the heart and blood

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

2002 CLINICAL PRACTICE GUIDELINES MANAGEMENT OF LIPID ABNORMALITIES

2002 CLINICAL PRACTICE GUIDELINES MANAGEMENT OF LIPID ABNORMALITIES OVERVIEW The Management of Lipid Abnormalities guideline is based on the recommendations outlined in the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,

More information

Dietary omega-3 fatty acids for women. Biomedicine & Pharmacotherapy January 2, 2007 [Early Epub]

Dietary omega-3 fatty acids for women. Biomedicine & Pharmacotherapy January 2, 2007 [Early Epub] Dietary omega-3 fatty acids for women 1 Biomedicine & Pharmacotherapy January 2, 2007 [Early Epub] Jean-Marie Bourre [ALA Alpha-linolenic acid, plant derived 18-carbon long omega-3 fatty acid. Primarily

More information

L XI: DRUGS: 1. STATINS

L XI: DRUGS: 1. STATINS L XI: DRUGS: 1. STATINS Statins Classification Mechanism of action Pleiotropic effects Efficacy: -Lipid level -CV events Indications Aggressive lipid lowering Initiation and monitoring Toxicity and drug

More information

Dyslipidemia Mahmoud Hassanein, MD Plasma Lipoproteins Relation of lipoproteins to atherosclerosis: Measurement of plasma lipids

Dyslipidemia Mahmoud Hassanein, MD Plasma Lipoproteins Relation of lipoproteins to atherosclerosis: Measurement of plasma lipids Dyslipidemia 1. Mahmoud Hassanein, MD Professor of Cardiology - Alexandria University Plasma Lipoproteins * Lipoproteins are large macromolecular complexes that transport cholesterol and triglycerides

More information

Fatty Acids carboxylic acids

Fatty Acids carboxylic acids Triglycerides (TG) should actually be called triacylglycerols (TAG). TG or TAG are molecules with a glycerol (a carbohydrate) backbone to which are attached three acyl groups. They represent a concentrated

More information

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011). Page 1 of 10 ANALYTE NAME AND STRUCTURE TERIFLUNOMIDE Teriflunomide TRADE NAME Aubagio CATEGORY Antimetabolite TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND sclerosis. The

More information

REACH Risk Evaluation to Achieve Cardiovascular Health

REACH Risk Evaluation to Achieve Cardiovascular Health Dyslipidemia and obesity History: A 13-year-old girl is seen for a routine clinic follow-up visit. She has been previously healthy, but her growth curve shows increasing body mass index (BMI) percentiles

More information

Who are the treatment populations?

Who are the treatment populations? The 2013 American Heart Association/American College of Cardiology (AHA/ACC) Guidelines utilize an evidence-based Clinical Question (CQ) approach. The AHA/ACC evidence-based format takes into account the

More information

Beneficial effects of Bios Life 2 (Dietary Fiber Supplement) in patients with dyslipidemia.

Beneficial effects of Bios Life 2 (Dietary Fiber Supplement) in patients with dyslipidemia. Beneficial effects of Bios Life (Dietary Fiber Supplement) in patients with dyslipidemia. Balajadia E., Valerio A., and Yumul N. Abstract The importance of dietary fibers in lowering cholesterol levels

More information

ANTIHyperlipidemiC DRUGS

ANTIHyperlipidemiC DRUGS ANTIHyperlipidemiC DRUGS Lipids are transported in the blood by being incorporated within lipoproteins. Lipoproteins are macromolecular disc like complexes of lipids and specific proteins called apoproteins.

More information

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. AMBULANCE SERVICES Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Maintenance of abstinence in alcohol dependence

Maintenance of abstinence in alcohol dependence Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly

More information

IMPLANTABLE INFUSION PUMP

IMPLANTABLE INFUSION PUMP IMPLANTABLE INFUSION PUMP Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and

More information

DEEP BRAIN STIMULATION

DEEP BRAIN STIMULATION DEEP BRAIN STIMULATION Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline

More information

Comparison of Criteria for reimbursing KUVAN (sapropterin dihydrochloride) 100 mg tablets for the treatment of Phenylketonuria (PKU)

Comparison of Criteria for reimbursing KUVAN (sapropterin dihydrochloride) 100 mg tablets for the treatment of Phenylketonuria (PKU) Payment length of time covered by manufacturer Initial Criteria for payment of therapy by manufacturer Pregnant Patients Comparison of Criteria for reimbursing KUVAN (sapropterin dihydrochloride) 100 mg

More information

THE ALOSETRON REMS PROGRAM

THE ALOSETRON REMS PROGRAM THE ALOSETRON REMS PROGRAM Prescriber Education Slide Deck Understanding the Benefits and Risks of Alosetron 1 Table of Contents Important Modified Alosetron REMS Program Slide 3 Section 1 Purpose Slide

More information

HYPERTENSION ASSOCIATED WITH RENAL DISEASES

HYPERTENSION ASSOCIATED WITH RENAL DISEASES RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein

More information

Simeon Margolis, MD, PhD

Simeon Margolis, MD, PhD Simeon Margolis, MD, PhD Decisions on when to lower LDL cholesterol are based on a combination of risk status and the LDL cholesterol Cigarette smoking Hypertension HDL cholesterol

More information

Pharmacotherapy in the Elderly. Judy MY Wong

Pharmacotherapy in the Elderly. Judy MY Wong Pharmacotherapy in the Elderly Judy MY Wong judywong@berkeley.edu Percentage of population with prescription and number of medication per individual increase with age Definitions Pharmacology: pharmakon

More information

Pantesin Effective support for heart healthy cholesterol levels*

Pantesin Effective support for heart healthy cholesterol levels* Pantesin Effective support for heart healthy cholesterol levels* { Pantesin Effective support for heart healthy cholesterol levels* Many health-conscious adults keeping a watchful eye on their cholesterol

More information

An Introduction to the Improved FDA Prescription Drug Labeling

An Introduction to the Improved FDA Prescription Drug Labeling An Introduction to the Improved FDA Prescription Drug Labeling 1 Introduction Mary E. Kremzner, Pharm.D. CDR, U.S. Public Health Service Deputy Director, Division of Drug Information Center for Drug Evaluation

More information

Limitation of use: Onivyde is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas (1).

Limitation of use: Onivyde is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.67 Subject: Onivyde Page: 1 of 5 Last Review Date: September 15, 2016 Onivyde Description Onivyde

More information

Is the 10 mg Doxepin Capsule a Suitable Substitute for the Silenor 6 mg Tablet?

Is the 10 mg Doxepin Capsule a Suitable Substitute for the Silenor 6 mg Tablet? Is the 10 mg Doxepin Capsule a Suitable Substitute for the Silenor 6 mg Tablet? The question has arisen as to whether or not a generic version of doxepin, in particular the 10 mg capsule, might be substituted

More information

Not All Clinical Trials Are Created Equal Understanding the Different Phases

Not All Clinical Trials Are Created Equal Understanding the Different Phases Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact

More information

scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL INITIATION ZACKS ESTIMATES

scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL INITIATION ZACKS ESTIMATES Small-Cap Research October 30, 2014 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Matinas BioPharma Holdings, Inc. (MTNB-OTCQB)

More information

An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia

An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates

More information

How Effective is Dietary Therapy for Marked Hypertriglyceridemia?

How Effective is Dietary Therapy for Marked Hypertriglyceridemia? How Effective is Dietary Therapy for Marked Hypertriglyceridemia? Kathy Rhodes, PhD, RDN Cardiovascular Medicine Frankel Cardiovascular Center University of Michigan Ann Arbor, MI September 19, 2015 If

More information

L-CARNITINE. Department of clinical toxicology Loghman poison center. Mitra Rahimi MD

L-CARNITINE. Department of clinical toxicology Loghman poison center. Mitra Rahimi MD L-CARNITINE Department of clinical toxicology Loghman poison center Mitra Rahimi MD L-Carnitine (levocarnitine) is an amino acid that is vital to mitochondrial utilization of fatty acids. INDICATIONS:

More information

AUTOMATIC EXTERNAL DEFIBRILLATOR AND WEARABLE CARDIOVERTER DEFIBRILLATOR

AUTOMATIC EXTERNAL DEFIBRILLATOR AND WEARABLE CARDIOVERTER DEFIBRILLATOR DEFIBRILLATOR Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must

More information

The Incredible Benefits of Omega-3 Fish Oil

The Incredible Benefits of Omega-3 Fish Oil The Incredible Benefits of Omega-3 Fish Oil Fish oil would not outrank the rest of the supplements in America, and be the most indemand dietary capsule in the list if the benefits of Omega-3 fish oil were

More information